Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclin I family member 2 (CCNI2)
- Target
- CCNI2
- Molecular classification
- Cyclin, CDK activator, Other (cell cycle regulatory protein)
01
Overview
Cyclin I family member 2 (CCNI2) is a member of the cyclin protein family and a homolog of cyclin I (CCNI). It functions as a novel activator of cyclin-dependent kinase 5 (CDK5), differing from other cyclin family activators by localizing CDK5 to the cytoplasm and cell membrane rather than the nucleus. CCNI2 regulates cell cycle progression and cell proliferation, with its depletion leading to decreased cell proliferation and impaired cell cycle progression. Recent research reveals CCNI2 is abnormally elevated in pancreatic cancer and promotes tumor cell proliferation and migration via the PI3K/AKT signaling pathway, highlighting its potential importance as a prognostic marker and as a therapeutic target in cancer. The full physiological and pathological roles of CCNI2 are still being investigated.
- Other names
- Cyclin-I2CCNI2FLJ16793cyclin I-like protein
02
Mechanism of action
As a therapeutic target, inhibition is theorized to impair cell proliferation via interference with PI3K/AKT signaling in cancers expressing high CCNI2
03
Biological functions
Cell cycle regulation (G1/S transition and progression)Regulation of cell proliferationActivation of CDK5 kinase activity
04
Disease associations
Cancer (notably implicated in pancreatic cancer progression)Other (potential biomarker and novel cancer target)
05
Safety considerations
Not well described; targeting fundamental cell cycle proteins often risks effects on normal proliferative tissues
06
Biomarkers
High CCNI2 expression is associated with poor prognosis in pancreatic cancer and may serve as a prognostic marker
Beyond the preview
Go deeper on Cyclin I family member 2 (CCNI2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyclin I family member 2 (CCNI2).